SURGISENSE CORPORATION

Medtech · Private

Real-time tissue oxygenation imaging system integrated with colonoscope to detect pre-malignant polyps during screening

Grants
$2.0M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
16
5 granted · 11 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Oxygen Mapping System for Enhanced Colonoscopic Neoplasm Detection$1,072,220
Federal grantDepartment of Health and Human Services · Phase II · Oxygen Mapping System for Enhanced Colonoscopic Neoplasm Detection$927,780
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1727PREEMIE-PACER, LLC——
1728NUVAIRA, INC.—$164M
1729Nicolaos Christodoulides——
1730SURGISENSE CORPORATION——
1731Sera Prognostics—$150M
1732Trevi Therapeutics, Inc.—$118M
1733EPOULOSIS THERAPEUTICS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 5 granted of 16

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.